Anzeige
+++Bodendrohne als Startrampe für Luftdrohnen: Lockt das die Militärs an?+++
Portfolio Tracker
Alle Depots an einem Ort. Dein Gesamtvermögen immer im Blick, tiefgründige Renditeanalysen und Dividendenplaner.
Anzeige
EQS-News

Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications 28.05.2026, 16:41 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Sino Biological / Key word(s): Financial
Sino Biological's Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab's Protein Design Study Published in Nature Communications

28.05.2026 / 16:41 CET/CEST
The issuer is solely responsible for the content of this announcement.


HOUSTON, TEXAS - May 28, 2026 (NEWMEDIAWIRE) - Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced that its gene synthesis and cell-free protein expression workflow was used in a recent study by Tencent AI for Life Sciences Lab published in Nature Communications, enabling rapid experimental validation of AI-designed proteins with improved activity, stability, and multifunctionality. 

Bridging AI Protein Design and Experimental Validation

Artificial intelligence has significantly accelerated protein amino acid sequence design, however, translating these computational designs into functional proteins remains a key challenge in protein engineering. Protein activity, stability, folding, and expression are influenced by complex structural and biochemical factors, often leading to discrepancies between in silico predictions and experimental outcomes.

To address this gap, the study introduced an Ontology Reinforcement Iteration (ORI) framework, integrating protein ontology with reinforcement learning from wet-lab feedback. Experimental data, including protein expression levels and functional activity, were continuously fed back into the model enabling iterative optimization of protein sequences and improved design accuracy. 

Cell-Free Protein Synthesis Accelerates the AI Design Loop

The researchers subsequently utilized Sino Biological’s XPressMAX™ Cell-Free Protein Synthesis Kit to enable rapid protein expression and functional screening. Protein-coding sequences cloned into the kit’s expression vector and added to the proprietary cell-free reaction system supported rapid design–build–test cycles.

Using this workflow, the team engineered a lysozyme with over 100-fold higher activity than the natural enzyme, developed a thermostable chitinase retaining activity at 85°C, and successfully expressed bifunctional enzymes with improved performance compared with naturally occurring multifunctional enzymes.

XPressMAX™Cell-Free Protein Synthesis Kit

Key features include:

  • Ultra-fast synthesis: protein expression completed in as little as 3 hours
  • High screening efficiency: optimized for VHH, scFv, and miniproteins
  • Flexible template support: compatible with plasmid and linear DNA templates
  • Disulfide bond friendly: enables expression of complex disulfide-bonded proteins without additional enhancers
  • Cost-effective performance: reduced operational time and cost
  • Scalable supply: suitable for high-throughput and industrial applications 

About Sino Biological

Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. With the US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech (part of Sino Biological) in Canada, Sino Biological delivers tailored, localized solutions to meet diverse research needs worldwide. Serving researchers in over 90 countries, the company maintains a stringent quality management system across all products.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on Sino Biological management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological has no control. Sino Biological assumes no obligation to update these forward-looking statements and does not intend to do so.

For media inquiries or partnership opportunities, please contact:

Sino Biological, Inc.
gmo@sinobiological.cn
www.sinobiological.com

View the original release on www.newmediawire.com


News Source: Sino Biological


28.05.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Sino Biological
United States
ISIN: CNE100004Q23
EQS News ID: 2335390

 
End of News EQS News Service

2335390  28.05.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer